BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 30365164)

  • 1. Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis.
    Kim HL; An J; Park JA; Park SH; Lim YS; Lee EK
    Hepatology; 2019 Apr; 69(4):1599-1613. PubMed ID: 30365164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
    Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances.
    Nouso K; Tanaka H; Uematsu S; Shiraga K; Okamoto R; Onishi H; Nakamura S; Kobayashi Y; Araki Y; Aoki N; Shiratori Y
    J Gastroenterol Hepatol; 2008 Mar; 23(3):437-44. PubMed ID: 17683496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performing Gadoxetic Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Suh CH; Kim KW; Park SH; Kim SY; Woo DC; Shin S; Pyo J; Shinagare AB; Ramaiya NH; Lim YS
    AJR Am J Roentgenol; 2018 Feb; 210(2):W63-W69. PubMed ID: 29091004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis.
    Nahon P; Najean M; Layese R; Zarca K; Segar LB; Cagnot C; Ganne-Carrié N; N'Kontchou G; Pol S; Chaffaut C; Carrat F; Ronot M; Audureau E; Durand-Zaleski I; ; ; ;
    JHEP Rep; 2022 Jan; 4(1):100390. PubMed ID: 34977518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.
    Arguedas MR; Chen VK; Eloubeidi MA; Fallon MB
    Am J Gastroenterol; 2003 Mar; 98(3):679-90. PubMed ID: 12650806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
    Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis.
    Patel D; Terrault NA; Yao FY; Bass NM; Ladabaum U
    Clin Gastroenterol Hepatol; 2005 Jan; 3(1):75-84. PubMed ID: 15645408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol.
    Kim HA; Kim KA; Choi JI; Lee JM; Lee CH; Kang TW; Ku YM; Lee SL; Park YS; Yoon JH; Kim SH; Choi MH
    BMC Cancer; 2017 Dec; 17(1):877. PubMed ID: 29268722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Utility Analysis of Non-Contrast Abbreviated Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance in Cirrhosis.
    Decharatanachart P; Pan-Ngum W; Peeraphatdit T; Tanpowpong N; Tangkijvanich P; Treeprasertsuk S; Rerknimitr R; Chaiteerakij R
    Gut Liver; 2024 Jan; 18(1):135-146. PubMed ID: 37560799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.
    Sangmala P; Chaikledkaew U; Tanwandee T; Pongchareonsuk P
    Asian Pac J Cancer Prev; 2014; 15(20):8993-9004. PubMed ID: 25374242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis.
    Andersson KL; Salomon JA; Goldie SJ; Chung RT
    Clin Gastroenterol Hepatol; 2008 Dec; 6(12):1418-24. PubMed ID: 18848905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma.
    Kim SY; An J; Lim YS; Han S; Lee JY; Byun JH; Won HJ; Lee SJ; Lee HC; Lee YS
    JAMA Oncol; 2017 Apr; 3(4):456-463. PubMed ID: 27657493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of EOB-MRI for Hepatocellular Carcinoma in Japan.
    Nishie A; Goshima S; Haradome H; Hatano E; Imai Y; Kudo M; Matsuda M; Motosugi U; Saitoh S; Yoshimitsu K; Crawford B; Kruger E; Ball G; Honda H
    Clin Ther; 2017 Apr; 39(4):738-750.e4. PubMed ID: 28363694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms.
    Parikh ND; Singal AG; Hutton DW; Tapper EB
    Am J Gastroenterol; 2020 Oct; 115(10):1642-1649. PubMed ID: 32530829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial.
    An C; Kim DY; Choi JY; Han KH; Roh YH; Kim MJ
    BMC Cancer; 2018 Sep; 18(1):915. PubMed ID: 30249190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population.
    Cucchetti A; Trevisani F; Cescon M; Ercolani G; Farinati F; Poggio PD; Rapaccini G; Nolfo MAD; Benvegnù L; Zoli M; Borzio F; Giannini EG; Caturelli E; Chiaramonte M; Pinna AD;
    J Hepatol; 2012 May; 56(5):1089-1096. PubMed ID: 22245900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    Mueller PP; Chen Q; Ayer T; Nemutlu GS; Hajjar A; Bethea ED; Peters MLB; Lee BP; Janjua NZ; Kanwal F; Chhatwal J
    J Hepatol; 2022 Jul; 77(1):55-62. PubMed ID: 35157959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening.
    Vietti Violi N; Lewis S; Liao J; Hulkower M; Hernandez-Meza G; Smith K; Babb JS; Chin X; Song J; Said D; Kihira S; Sirlin CB; Reeder SB; Bashir MR; Fowler KJ; Ferket BS; Sigel K; Taouli B
    Eur Radiol; 2020 Nov; 30(11):6003-6013. PubMed ID: 32588209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.
    Bolondi L; Sofia S; Siringo S; Gaiani S; Casali A; Zironi G; Piscaglia F; Gramantieri L; Zanetti M; Sherman M
    Gut; 2001 Feb; 48(2):251-9. PubMed ID: 11156649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.